Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-center, Phase II Study of Serplulimab Combined With XELOX and Bevacizumab Neoadjuvant Therapy for Locally Advanced Rectal Cancer

NCT07854964 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT07854964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07854964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-center, Phase II Study of Serplulimab Combined With XELOX and Bevacizumab Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Lead sponsor
Tang-Du Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
May 15, 2031
Enrollment
48 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer